{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T02:20:26Z","timestamp":1787710826941,"version":"build-2784847793"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":70,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Natural Science Foundation Project of Hunan Province"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Urothelial carcinoma is a common malignancy of the urinary tract and occurs predominantly in elderly men. Although surgery, chemotherapy, and radiotherapy remain the main treatment options, their efficacy in advanced disease is often limited, particularly in elderly patients with comorbidities or poor surgical tolerance. Antibody-drug conjugates (ADCs) combined with immune checkpoint inhibitors have recently emerged as a promising therapeutic strategy. We report the case of a 79-year-old man with advanced urothelial carcinoma who declined radical cystectomy and received disitamab vedotin plus toripalimab. Histopathological examination confirmed high-grade muscle-invasive urothelial carcinoma, and supplementary immunohistochemistry showed HER2 expression of 1+. FISH\/ISH and PD-L1 testing were not performed. The patient received treatment every 3 weeks over 2 consecutive days, with disitamab vedotin on day 1 and toripalimab on day 2. After 6 cycles, imaging showed marked tumor regression, and repeat transurethral resection of the tumor bed revealed no residual tumor cells, consistent with pathological complete response. The treatment was generally well tolerated, with only mild fatigue and nausea. This case suggests that disitamab vedotin combined with toripalimab may have activity in selected patients with advanced urothelial carcinoma, including those with low HER2 expression. However, the findings should be interpreted cautiously, and further studies are needed to clarify the role of this regimen and the value of predictive biomarkers.<\/jats:p>","DOI":"10.1186\/s12894-026-02194-2","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T05:44:01Z","timestamp":1781675041000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A case report of pathological complete response in an elderly patient with advanced urothelial carcinoma treated with disitamab vedotin plus toripalimab"],"prefix":"10.1186","volume":"26","author":[{"given":"Liang","family":"Songlin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Yunxun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Peiyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Mingyong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"2194_CR1","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, et al. Cancer statistics, 2025. CA Cancer J Clin. 2025;75:10\u201345.","journal-title":"CA Cancer J Clin"},{"key":"2194_CR2","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","volume":"87","author":"AG Van der Heijden","year":"2025","unstructured":"Van der Heijden AG, Bruins HM, Carrion A, et al. EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 2025;87:582\u2013600.","journal-title":"Eur Urol"},{"key":"2194_CR3","first-page":"1315","volume":"29","author":"X Yin","year":"2024","unstructured":"Yin X, Lu M, Yu Z, et al. A novel antibody-drug conjugate: disitamab vedotin. Chin J Clin Pharmacol Ther. 2024;29:1315\u201320.","journal-title":"Chin J Clin Pharmacol Ther"},{"key":"2194_CR4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/1078-0432.CCR-20-2488","volume":"27","author":"X Sheng","year":"2021","unstructured":"Sheng X, Yan X, Wang L, et al. Phase II study of RC48-ADC. Clin Cancer Res. 2021;27:43\u201351.","journal-title":"Clin Cancer Res"},{"key":"2194_CR5","doi-asserted-by":"publisher","first-page":"4584","DOI":"10.1200\/JCO.2021.39.15_suppl.4584","volume":"39","author":"X Sheng","year":"2021","unstructured":"Sheng X, He Z, Han W, et al. RC48-C009 study. J Clin Oncol. 2021;39:4584.","journal-title":"J Clin Oncol"},{"key":"2194_CR6","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.annonc.2024.12.002","volume":"36","author":"L Zhou","year":"2025","unstructured":"Zhou L, Yang KW, Zhang S, et al. RC48-C014 study. Ann Oncol. 2025;36:331\u20139.","journal-title":"Ann Oncol"},{"key":"2194_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/1541-7786.MCR-19-0582","volume":"18","author":"P Khongorzul","year":"2020","unstructured":"Khongorzul P, Ling CJ, Khan FU, et al. Antibody\u2013drug conjugates review. Mol Cancer Res. 2020;18:3\u201319.","journal-title":"Mol Cancer Res"},{"key":"2194_CR8","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.trecan.2023.01.003","volume":"9","author":"J Fuentes-Antras","year":"2023","unstructured":"Fuentes-Antras J, Genta S, Vijenthira A, et al. ADC combination strategies. Trends Cancer. 2023;9:339\u201354.","journal-title":"Trends Cancer"},{"key":"2194_CR9","first-page":"129","volume":"15","author":"GW Long","year":"2023","unstructured":"Long GW, Wang DW, Ye ZQ. Bladder-preserving treatment. J Mod Urogenit Oncol. 2023;15:129\u201332.","journal-title":"J Mod Urogenit Oncol"},{"key":"2194_CR10","unstructured":"Wei Q, Li P, Yang T et al. Combination therapies with antibody-drug con jugates in solid tumors."}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-026-02194-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-026-02194-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-026-02194-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T01:56:22Z","timestamp":1787709382000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12894-026-02194-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2194"],"URL":"https:\/\/doi.org\/10.1186\/s12894-026-02194-2","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"9 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study is a retrospective case report and was exempt from formal ethical approval in accordance with institutional policy (the First Affiliated Hospital of Hengyang Medical College, University of South China). All procedures were conducted in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"210"}}